



Established and Emerging

Biomarkers

in Heart Failure with Preserved Ejection Fraction

13.-15.10.2012
Graz, Austria

Scientific Chairs: Prof. Burkert Pieske, Austria
Prof. Gerasimos Filippatos, Greece
Prof. Alan Maisel, USA

Organised by the Ludwig-Boltzmann-Institute for Translational Heart Failure Research, Graz



Ludwig Boltzmann Institute
Translational Heart Failure Research



EUROPEAN
SOCIETY OF
CARDIOLOGY®



HEART FAILURE
ASSOCIATION
OF THE ESC



Medical University of Graz

Dear Friends,

a hearty welcome to the first "International Symposium on Established and Emerging Biomarkers in Heart Failure with Preserved Ejection Fraction".

Heart Failure with Preserved Ejection Fraction (HFpEF) is a condition that affects over 50% of the Heart Failure population. Symptomatic HFpEF is only the tip of the iceberg, since very prevalent risk factors, such as hypertension and diabetes induce diastolic dysfunction. Asymptomatic diastolic dysfunction largely increases the risk for overt heart failure, and early detection may bear potential for prevention.

Large clinical endpoint trials in HFpEF failed in significantly reducing clinical endpoints. A better, earlier and individualized diagnostic strategy for patients at risk for HFpEF or with overt HFpEF is urgently needed. Also, a better assessment of comorbidities that contribute to signs and symptoms of these patients is mandatory. Clinical trialists ask for new tools that allow a better and more effective trial design for new therapies. Last but not least, a thorough monitoring of risk and therapeutic effects is needed in this condition.

Blood- and urine derived emerging biomarkers as diagnostic and prognostic tools may help to fill these clinical needs. The purpose of the Symposium, which takes place from October 13 to October 15, 2012, in Graz, Austria is an in-depth discussion of these issues in order to lay the ground for future developments aimed at improving life for millions of affected people around the world.

The Symposium is organized by the Ludwig-Boltzmann-Institute for Heart Failure Research. The Committee on HFpEF of the Heart Failure Association of the European Society of Cardiology is intimately involved in the program. We also want to thank the Sponsors of the Symposium, who have made this project possible.

Finally, we want to welcome the Speakers, Discussants, Chairs and all Contributors and we wish all of us a fruitful and successful meeting.

Prof. Burkert Pieske

Prof. Gerasimos Filippatos

Prof. Alan Maisel

Saturday, October 13, 2012

13.00-14.00 **Welcome Reception at Aula der Alten Universität**
Burkert Pieske, Gerasimos Filippatos, Alan Maisel

14.00-22.00 **Bus Tour to Southern Styria**
Visit to Winery – Wine tasting
Tour through mountains on Slovenian Border
Dinner in typical local Restaurant

Sunday, October 14, 2012

08.30-08.45 **Welcome and Introduction**
Burkert Pieske, Gerasimos Filippatos, Alan Maisel

Session I: 08.45-10.10

Heart Failure with Preserved Ejection Fraction

Chairs: Walter Paulus, Amsterdam; Jan A. Staessen, Leuven

08.45-09.00 The concept of HFPEF
Burkert Pieske, Graz

09.00-09.20 Pathophysiology of HFPEF
Michael Zile, Charleston

09.20-09.40 Diagnosing HFPEF: Where do we go from here?
Walter Paulus, Amsterdam

09.40-10.00 The potential of biomarkers in HFPEF
Alan Maisel, San Diego

10.00-10.10 General Discussion

10.10-10.30 **Coffee Break**



Scientific program

Sunday, October 14, 2012

Scientific program

Session II: 10.30-12.10

Current standards and limits in diagnosing HFPEF

Chairs: Marco Guazzi, Milano; Michael Zile, Charleston

- 10.30-10.50** Standards in Imaging and Hemodynamic Assessment
Otto Smiseth, Oslo
- 10.50-11.00** Novel imaging parameters and insights from PARAMOUNT and Aldo-DHF
Elisabeth Kraigher-Krainer, Graz
- 11.00-11.20** Left atrial size and function: Key for diagnosing HFPEF?
Ken McDonald, Dublin
- 11.20-11.40** Could biomarkers substitute imaging in diagnosing HFPEF?
Alan Fraser, Cardiff
- 11.40-12.00** Biomarkers in hospitalisation HFPEF
Mihai Gheorghiade, Chicago
- 12.00-12.10** General Discussion
- 12.10-13.15** **Lunch**

Session III: 13.15-14.45

Biochemical diagnosis in HFPEF – Natriuretic peptides

Chairs: Javier Diez, Pamplona; Caroly Lam, Singapore

- 13.15-13.35** Natriuretic peptides – overview in HFPEF
Alan Maisel, San Diego
- 13.35-13.45** Glycosylation of Natriuretic Peptides: Relevance for HFPEF?
Helge Rosjo, Lorenskog
- 13.45-13.55** Natriuretic peptides: Cut-off values and pitfalls
Burkert Pieske, Graz
- 13.55-14.15** Natriuretic peptides and prognosis in HFPEF
Inder Anand, Minnesota
- 14.15-14.35** Increasing diagnostic accuracy by adding natriuretic peptides to imaging
Carsten Tschöpe, Berlin
- 14.35-14.45** General Discussion
- 14.45-15.00** **Coffee Break**

Session IV: 15.00-16.40

Emerging serum biomarkers in HFPEF (I)

Chairs: Gerasimos Filippatos, Athens; Alan Fraser, Cardiff

- 15.00-15.20** Galectin-3
Inder Anand, Minnesota
- 15.20-15.30** Galectin-3 in the Aldo-DHF Trial
Frank Edelmann, Göttingen
- 15.30-15.50** soluble ST-2
Thomas Müller, Linz
- 15.50-16.10** Fibrillar collagen-derived peptides
Javier Diez, Pamplona
- 16.10-16.30** (hs)Troponins
Hugo A. Katus, Heidelberg
- 16.30-16.40** General Discussion
- 16.40-17.00** **Coffee Break**

Session V: 17.00-18.30

Emerging serum biomarkers in HFPEF (II)

Chairs: Inder Anand, Minnesota; Hugo A. Katus, Heidelberg

- 17.00-17.20** Emerging Biomarkers: Looking beyond the Fence
Helge Rosjo, Lorenskog
- 17.20-17.40** Midregional biomakers
Gerasimos Filippatos, Athen
- 17.40-17.50** Hormones as biomarkers in HFPEF?
Andreas Tomaschitz, Graz
- 17.50-18.00** miRNAs – diagnostic signatures for HFPEF etiologies?
Thomas Thum, Hannover
- 18.00-18.20** Use of biomarkers as inclusion and outcome criterion in HFPEF trials
Mihai Gheorghiade, Chicago
- 18.20-18.30** General Discussion
- 19.30** **Walk from Hotel to Restaurant and Dinner**

Monday, October 15, 2012

Scientific program

Session VI: 08:30-10.00

Novel avenues in biomarker research in HFPEF

Chairs: Mark Richards, Singapore/Melbourne; Ken McDonald, Dublin

- 08.30-08.50** Urine-derived biomarkers: Potential in HFPEF?
Harald Mischak, Hannover/Glasgow
- 08.50-09.10** Gender, sex hormones and natriuretic peptides
Carolyn Lam, Singapore
- 09.10-09.30** HFPEF biomarkers: Age and renal function
Hans-Peter Brunner-La Rocca, Maastricht
- 09.30-09.50** Biomarkers in the transition from hypertensive heart disease to HFPEF
Jan A. Staessen, Leuven
- 09.50-10.00** General Discussion
- 10.00-10.30** **Coffee Break**

Session VII: 10.30-12.20

Biomarkers use in clinical trials

Chairs: Burkert Pieske, Graz; Gerasimos Filippatos, Athens

- 10.30-10.50** Biomarker based treatment in HFPEF?
Alan Maisel, San Diego
- 10.50-11.10** Multimaker approach or “one marker fits all” in HFPEF? – Experience from an Asian cohort
Mark Richards, Singapore/Melbourne
- 11.10-11.30** Use of biomarkers in home monitoring: The HABIT-2 PRESERVED trial and INTENSE-HF
Alan Maisel, San Diego
- 11.30-11.50** Will biomarkers be acceptable as surrogate markers in HFPEF trials – views from regulatory agencies?
Giuseppe Rosano, Rome
- 11.50-12.10** Biomarkers in HFPEF Trials – Expectations from Pharmaceutical Industry
Thomas Langenickel, Novartis, Basel
- 12.10-12.20** General Discussion
- 12.20-12.30** **Coffee Break**

Monday, October 15, 2012

Session VIII: 12.30-13.30

Emerging Biomarkers – a view from industry

Chairs: Alan Maisel, San Diego; Giuseppe Rosano, Rome

12.30-12.45 Biomarker Research at BG Medicine
Aram Adourian, Boston

12.45-13.00 Biomarkers Research at Alere
Kevin Keegan, San Diego

13.00-13.15 Biomarker Research at Critical Diagnostics
James Snider, San Diego

13.15-13.30 Biomarker Research at Bayer AG
Frank Kramer, Wuppertal

13.30-13.45 **Next steps and concluding remarks**
Burkert Pieske, Gerasimos Filippatos, Alan Maisel

13.45 **Lunch**

15.00-17.00 Guided tour through Graz

19.00 **Dinner**



Scientific program

Anand Inder, MD, FRCP, D Phil (Oxon.)

Professor of Medicine, University of Minnesota Medical School
Director, Heart Failure Program,
VA Medical Center 111C Minneapolis MN 55417
anand001@umn.edu

Brunner-La Rocca Hans-Peter, Prof. Dr.

Director Heart Failure Clinic
Acting Director Department of Cardiology
Maastricht University Medical Centre
P. Debyelaan 25
PO Box 5800
6202 AZ Maastricht
The Netherlands
hp.brunnerlarocca@mumc.nl

Diez Javier, Prof. Dr. MD

University Clinic, University of Navarra
Department of Cardiology and
Cardiovascular Surgery
Division de Fisiopatología, Cardiovascular,
Facultad de Medicina, C/ Irunlarrea s/n,
31080 Pamplona, Spain
jadimar@unav.es
ecasadol@unav.es

Edelmann Frank, Priv. Doz. Dr.

Universitätsmedizin Göttingen
Herzzentrum Göttingen
Öffentlichkeitsarbeit
Robert-Koch-Str. 40
37099 Göttingen, Germany
fedelmann@med.uni-goettingen.de

Filippatos Gerasimos, Prof. MD

University of Athens, Department of Cardiology,
Heart Failure Unit
28 Doukissis Plakentias,
11523 Athens, Greece
geros@otenet.gr

Fraser Alan G., Prof. MD

Wales Heart Research Institute
Cardiff University School of Medicine
Heath Park, Cardiff CF14 4XN, UK;
FraserAG@cardiff.ac.uk

Gheorghiade Mihai, MD FACC

Professor of Medicine and Surgery
Director of Experimental Therapeutics
Center for Cardiovascular Innovation
Northwestern University Feinberg School of
Medicine
645 North Michigan Ave, 1006
Chicago, IL 60601, USA
m-gheorghiade@northwestern.edu

Guazzi Marco, MD

Cardiopulmonary Laboratory, University of Milano
Cardiology Division, San Paolo Hospital,
Via A. di Rudini 8, 20142 Milano, Italy
marco.guazzi@unimi.it

Katus Hugo A., Prof. MD. PhD, FESC; FACC

University of Heidelberg
Medizinische Klinik (Kreihl-Klinik)
Head of Cardiology, Pneumology and Angiology
Speaker of the Department of Internal Medicine
Im Neuenheimer Feld 410
69120 Heidelberg, Germany
hugo.katus@med.uni-heidelberg.de
Sekretariat.Katus@med.uni-heidelberg.de

Kraigher-Krainer Elisabeth, Dr.

Department of Cardiology
Medical University Graz
Auenbruggerplatz 15
8036 Graz, Austria
elisabeth.kraigher-krainer@medunigraz.at

Lam Su Carolyn, Ass. Prof. MD

National University Health System Tower Block
1E Kent Ridge Road
Singapore 238216
carolyn_lam@nuhs.edu.sg

Maisel Alan S., Prof. MD

Professor of Medicine
Director, Coronary Care Unit and
Heart Failure Program,
Veterans Affairs San Diego Healthcare System
VA San Diego Healthcare System
3350 La Jolla Village Drive
Cardiology Section, mc 9111A
San Diego, California 92161
amaisel@ucsd.edu

McDonald Kenneth, Prof. MD

Heart Failure Unit,
St Vincent's University Hospital
Elm Park, Dublin 4, Ireland
kenneth.mcdonald@ucd.ie

Mischak Harald, Prof. Dr. Dr.

mosaiques diagnostics and therapeutics AG
Mellendorfer Strasse 7-9
D-30625 Hannover
Germany
mischak@mosaiques-diagnostics.com

Müller Thomas, OA. Priv. Doz

B&S Zentrallabor
Barmherzige Brüder und Barmherzige Schwestern
Seilerstätte 4, 4010 Linz, Austria
thomas.mueller@bs-lab.at

Speaker & Chairs

Paulus Walter J., Prof. MD

Institute for Cardiovascular Research
Vrije Universiteit Amsterdam,
Van der Boechorststraat 7,
1081 BT Amsterdam, The Netherlands
wj.paulus@vumc.nl

Pieske Burkert, Prof. Dr.

Director, LBI.HF & Department of Cardiology
Medical University Graz
Auenbruggerplatz 15
8036 Graz, Austria
burkert.pieske@medunigraz.at

Richards A. Mark, Prof. MD

National University Hospital
Cardiovascular Research Institute (CVRI), NUHS
5 Lower Kent Ridge Road Singapore 119074
mark.richards@cdhb.govt.nz

Rosano Giuseppe, Prof. MD

Director, Department of Medical Sciences,
IRCCS San Raffaele
Via della pisana, 235
00163 Rome
Italy
giuseppe.rosano@sanraffaele.it

Rosjo Helge MD, PhD

Deputy Head of Professor Omland Research Group
AND Head of Research Unit,
Division of Medicine, Akershus
University Hospital, Norway
helge.rosjo@medisin.uio.no

Smiseth Otto, Prof. MD

Oslo University Hospital
Division of Cardiovascular and Pulmonary Diseases
OUS HF Rikshospitalet Postboks
4950 Nydalen
0424 Oslo, Norway
Otto.Smiseth@rikshospitalet.no

Staessen Jan, Prof. MD

KU Leuven
Oude Markt 13
Bus 5005 3000 Leuven, Belgium
jan.staessen@med.kuleuven.be

Thum Thomas, Prof. Dr.

Hannover Medical School
IFB, Molecular and Translational Therapeutic
Strategies
OE 8886
Carl-Neuberg-Str. 1
30625 Hannover, Germany
Thum.Thomas@mh-hannover.de

Tomaschitz Andreas, Priv. Doz. Dr.

Department of Cardiology
Medical University Graz
Auenbruggerplatz 15
8036 Graz, Austria
andreas.tomaschitz@medunigraz.at

Tschöpe Carsten, Prof. Dr.

Universitätsklinikum Charité
Med. Klinik II - Kardiologie und Pulmologie
Campus Benjamin Franklin
Hindenburgdamm 30
12200 Berlin, Germany
Carsten.Tschoepe@charite.de

Zile Michael R., Prof. MD

Cardiology Division
Department of Medicine,
Gazes Cardiac Research Institute
Medical University of South Carolina,
135 Rutledge Ave., Suite 1201,
P.O. Box 250592, Charleston, SC 29425, USA
zilem@musc.edu

Industry:

Alere, Inc.

Keegan, Kevin, PhD
51 Sawyer Rd
Waltham, MA 02453-3448
United States
kkeegan@kesandassociates.com

Bayer Pharma AG

Global Biomarker Research
Kramer Frank, Dr.
Aprather Weg 18a
42096 Wuppertal; Germany
frank.kramer@bayerhealthcare.com

BG Medicine

Aram Adourian, PhD, VP Scientific Affairs
Global Director of Marketing
610 N Lincoln Street, Waltham, MA 02451
aadourian@BG-MEDICINE.COM

Critical Diagnostics


James V. Snider
3030 Bunker Hill St., Suite 117A
San Diego, CA 92109
Jsnider@criticaldiagnostics.com

Novartis Pharma AG

Thomas H Langenickel, MD
Director, Translational Medicine/Cardiovascular
Profiling
WSJ-210.5.27.3
CH-4002 Basel
Switzerland
thomas.langenickel@novartis.com

Scientific program

Guided tour through Graz



Platinum Sponsors:

BG Medicine
BAYER PHARMA AG, Austria
BAYER HealthCare, Germany
ABBOTT
BOEHRINGER INGELHEIM
ST. JUDE MEDIZINTECHNIK
T-MOBILE AUSTRIA
MAGNA STEYR

Gold Sponsors:

SERVIER International
MEDTRONIC Austria
BIOTRONIK
DAIICHI SANKYO AUSTRIA
NOVARTIS PHARMA
ROCHE DIAGNOSTICS
SIEMENS Healthcare Diagnostics
BIOSENSE Webster / JOHNSON & JOHNSON

Silver Sponsors:

VIFOR PHARMA
PHILIPS AUSTRIA
MENARINI PHARMA
PFIZER
SERVIER Austria
BIOMEDICA GROUP



Wir danken unseren Sponsoren / We thank our sponsors

Platinum Sponsors

Galectin-3



Abbott
Vascular

Boehringer
Ingelheim

ST. JUDE MEDICAL
MORE CONTROL. LESS RISK.

T-Mobile

MAGNA

Gold Sponsors

SERVIER



Medtronic



BIOTRONIK
excellence for life



Daiichi-Sankyo

NOVARTIS
caring and curing



SIEMENS

Biosense Webster
PRO. DR. HILF. Johnson & Johnson. WORLD OF EXCELLENCE

Silver Sponsors

Vifor Pharma

PHILIPS



Pfizer

BIOMEDICA
BIOMEDICA
GRUPPE
www.biomedica.ch